David A. Isenberg
AuthID: R-006-E33
11
TITLE: Adverse events of treatment with rituximab in patients with myositis
AUTHORS: Gilaberte, Sergio; Rua, Joana; Isenberg, David;
PUBLISHED: 2022, SOURCE: RHEUMATOLOGY, VOLUME: 62, ISSUE: 2
AUTHORS: Gilaberte, Sergio; Rua, Joana; Isenberg, David;
PUBLISHED: 2022, SOURCE: RHEUMATOLOGY, VOLUME: 62, ISSUE: 2
INDEXED IN: 
Scopus 
WOS
Scopus WOS12
TITLE: The use of combination monoclonal antibody therapies in lupus-where are we now?
AUTHORS: Rua, Joana; Dall'Era, Maria; Isenberg, David;
PUBLISHED: 2022, SOURCE: RHEUMATOLOGY, VOLUME: 62, ISSUE: 5
AUTHORS: Rua, Joana; Dall'Era, Maria; Isenberg, David;
PUBLISHED: 2022, SOURCE: RHEUMATOLOGY, VOLUME: 62, ISSUE: 5
INDEXED IN: Scopus WOS
Scopus WOS13
TITLE: Assessing outcomes in a lupus nephritis cohort over a 40-year period
AUTHORS: Gisca, E; Duarte, L; Farinha, F; Isenberg, DA;
PUBLISHED: 2021, SOURCE: RHEUMATOLOGY, VOLUME: 60, ISSUE: 4
AUTHORS: Gisca, E; Duarte, L; Farinha, F; Isenberg, DA;
PUBLISHED: 2021, SOURCE: RHEUMATOLOGY, VOLUME: 60, ISSUE: 4
INDEXED IN: Scopus WOS
Scopus WOS14
TITLE: Anti-protein C antibodies and acquired protein C resistance in SLE: novel markers for thromboembolic events and disease activity?
AUTHORS: Ramirez, GA; Mackie, I; Nallamilli, S; Pires, T; Moll, R; Pericleous, C; Isenberg, DA; Cohen, H; Efthymiou, M;
PUBLISHED: 2021, SOURCE: RHEUMATOLOGY, VOLUME: 60, ISSUE: 3
AUTHORS: Ramirez, GA; Mackie, I; Nallamilli, S; Pires, T; Moll, R; Pericleous, C; Isenberg, DA; Cohen, H; Efthymiou, M;
PUBLISHED: 2021, SOURCE: RHEUMATOLOGY, VOLUME: 60, ISSUE: 3
INDEXED IN: WOS
WOS15
TITLE: Prevalence and outcome of thrombocytopenia in systemic lupus erythematosus: single-centre cohort analysis
AUTHORS: Pires, TC; Caparros Ruiz, R; Gaspar, P; Isenberg, DA;
PUBLISHED: 2021, SOURCE: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, VOLUME: 39, ISSUE: 3
AUTHORS: Pires, TC; Caparros Ruiz, R; Gaspar, P; Isenberg, DA;
PUBLISHED: 2021, SOURCE: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, VOLUME: 39, ISSUE: 3
INDEXED IN: WOS
WOS16
TITLE: Fracture risk in systemic lupus erythematosus patients over 28 years
AUTHORS: Garelick, D; Pinto, SM; Farinha, F; Pires, T; Khan, E; Isenberg, D;
PUBLISHED: 2021, SOURCE: RHEUMATOLOGY, VOLUME: 60, ISSUE: 6
AUTHORS: Garelick, D; Pinto, SM; Farinha, F; Pires, T; Khan, E; Isenberg, D;
PUBLISHED: 2021, SOURCE: RHEUMATOLOGY, VOLUME: 60, ISSUE: 6
INDEXED IN: Scopus WOS
Scopus WOS17
TITLE: Can we predict if patients with SLE will require more than one cycle of rituximab?
AUTHORS: Gonzalez, RF; Abida, R; Gisca, E; Duarte, L; Isenberg, DA;
PUBLISHED: 2021, SOURCE: RHEUMATOLOGY
AUTHORS: Gonzalez, RF; Abida, R; Gisca, E; Duarte, L; Isenberg, DA;
PUBLISHED: 2021, SOURCE: RHEUMATOLOGY
INDEXED IN: WOS
WOS18
TITLE: Towards Precision Medicine in Systemic Lupus Erythematosus
AUTHORS: Elliott Lever; Marta R Alves; David A Isenberg;
PUBLISHED: 2020, SOURCE: PHARMACOGENOMICS & PERSONALIZED MEDICINE, VOLUME: 13
AUTHORS: Elliott Lever; Marta R Alves; David A Isenberg;
PUBLISHED: 2020, SOURCE: PHARMACOGENOMICS & PERSONALIZED MEDICINE, VOLUME: 13
INDEXED IN: Scopus WOS
Scopus WOS19
TITLE: "Mixed connective tissue disease": a condition in search of an identity Full Text
AUTHORS: Marta R Alves; David A Isenberg;
PUBLISHED: 2020, SOURCE: CLINICAL AND EXPERIMENTAL MEDICINE, VOLUME: 20, ISSUE: 2
AUTHORS: Marta R Alves; David A Isenberg;
PUBLISHED: 2020, SOURCE: CLINICAL AND EXPERIMENTAL MEDICINE, VOLUME: 20, ISSUE: 2
INDEXED IN: Scopus WOS
Scopus WOS20
TITLE: Why do some patients with systemic lupus erythematosus fail to respond to B-cell depletion using rituximab?
AUTHORS: Freitas, S; Mozo Ruiz, MM; Costa Carneiro, AC; Isenberg, DA;
PUBLISHED: 2020, SOURCE: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, VOLUME: 38, ISSUE: 2
AUTHORS: Freitas, S; Mozo Ruiz, MM; Costa Carneiro, AC; Isenberg, DA;
PUBLISHED: 2020, SOURCE: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, VOLUME: 38, ISSUE: 2
INDEXED IN: WOS
WOS